GDC-0575 dihydrochloride is primarily utilized in the field of oncology research. It functions as a potent and selective inhibitor of CHK1 (Checkpoint kinase 1), which plays a critical role in the DNA damage response pathway. By inhibiting CHK1, this compound disrupts the cell cycle checkpoint, leading to the accumulation of DNA damage and ultimately promoting cancer cell death. This mechanism makes it a promising candidate for enhancing the efficacy of DNA-damaging chemotherapeutic agents, such as cisplatin and gemcitabine, in various cancer treatments. Researchers are particularly interested in its potential to sensitize cancer cells to radiation therapy and chemotherapy, thereby improving therapeutic outcomes in resistant or aggressive tumors. Its application is predominantly in preclinical studies aimed at understanding its pharmacokinetics, pharmacodynamics, and safety profile for future clinical development.